Client name
ASML Holding N.V. (ASML)

Other parties involved
Institut des Radioelements

Nature of transaction
ASML has entered into a joint development agreement with IRE (Institut National des Radioéléments, Fleurus, Belgium) to allow IRE, with the support of ASML, to further develop and build an electron beamline that will be used to manufacture the medical isotope molybdenum 99 (Mo-99) in a new production process that is non-fission and waste-free. Mo-99 is used for diagnosing tens of millions people annually, making it the most commonly used medical radioisotope.

Value of transaction
<500 million

Date deal
01 October 2018

De Brauw involvement
Lead counsel

Other advisors
N/A, Breus van der Horst

De Brauw lead partner
Michael Schouten

De Brauw team
Michael Schouten, Heather Giannandrea, Oscar Lamme, Mustafa Al Saady and Ioana Patrascu